Literature DB >> 3995089

Binding and endocytosis of heparin by human endothelial cells in culture.

T Bârzu, P Molho, G Tobelem, M Petitou, J Caen.   

Abstract

Binding of heparin and low molecular weight heparin fragments (CY 222, Mr range 1500-8000) to human vascular endothelial cells was studied. Primary culture of human umbilical vein endothelial cells and either 125I or 3H-labeled heparin or [125I]CY 222 were used. Slow, saturable and specific binding was found. No other tested glycosaminoglycan, excepting a highly sulfated heparan fraction, was able to compete for heparin binding. Two groups of binding sites for [3H]heparin could be distinguished: one with high affinity (Kd = 0.12 microM) and another with lower affinity (Kd = 1.37 microM) and a relative large capacity of binding (1.16 X 10(7) molecules/cell) was calculated. The Kd for unlabeled heparin, as calculated from competition experiments, was 0.23 microM. Much lower affinity was calculated for unlabeled low molecular weight heparin fragments CY 222 (Kd = 4.3 microM) from competition experiments with [125I]CY 222. The binding reversibility was only partial for unfractionated heparin. Even by chasing with unlabeled compound, a fraction of 25-30% was not dissociable from endothelial cells. This fraction was much lower if incubation was carried out at 4 degrees C. The addition of basic proteins (histones) to the incubation medium greatly enhanced the undissociable binding at 37 degrees C, but not at 4 degrees C. The undissociable fraction of heparin was not available to degradation by purified microbial heparinase. These results suggest that a fraction of bound heparin is internalized by the vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995089     DOI: 10.1016/0167-4889(85)90177-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  27 in total

1.  Mast cell granule heparin proteoglycan induces lacunae in confluent endothelial cell monolayers.

Authors:  D Lagunoff; A Rickard
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 2.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Tissue average binding and equilibrium distribution: an example with heparin in arterial tissues.

Authors:  M A Lovich; E R Edelman
Journal:  Biophys J       Date:  1996-03       Impact factor: 4.033

Review 4.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

5.  Endothelial nitric oxide synthase activation is required for heparin receptor effects on vascular smooth muscle cells.

Authors:  Yaqiu Li; Leanna M Talotta-Altenburg; Kayli A Silimperi; Grace O Ciabattoni; Linda J Lowe-Krentz
Journal:  Am J Physiol Cell Physiol       Date:  2019-12-31       Impact factor: 4.249

6.  Membrane associated proteoglycans in rat testicular peritubular cells.

Authors:  L Bichoualne; B Thiébot; M Langris; P Barbey; H Oulhaj; J Bocquet
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

7.  In vitro stimulation of human endothelial cells by derivatized dextrans.

Authors:  D Letourneur; J Champion; F Slaoui; J Jozefonvicz
Journal:  In Vitro Cell Dev Biol       Date:  1993-01

8.  Sulfated polyanions block Chlamydia trachomatis infection of cervix-derived human epithelia.

Authors:  F R Zaretzky; R Pearce-Pratt; D M Phillips
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Heparin protects human endothelial cells infected by Rickettsia rickettsii.

Authors:  D J Silverman; L A Santucci; Z Sekeyova
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  Novel low molecular weight lignins as potential anti-emphysema agents: In vitro triple inhibitory activity against elastase, oxidation and inflammation.

Authors:  Bhawana Saluja; Jay N Thakkar; Hua Li; Umesh R Desai; Masahiro Sakagami
Journal:  Pulm Pharmacol Ther       Date:  2012-12-29       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.